Skip to main content

Advertisement

Table 2 Survival outcomes among all patients with AML-MRC (N = 262) and among those preselected to LDAC (n = 160)

From: Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

All patients with AML-MRC (N = 262)
  N Median OS, months (95%CI) Difference, months Hazard ratio (95% CI) K-M Estimated 1-Year survival Difference
AZA CCR AZA CCR AZA CCR  
Overall 129 133 8.9 (6.9, 12.9) 4.9 (3.8, 6.5) 4.0 0.74 (0.57, 0.97) 44.3% 26.9% 17.4%
Cytogenetic risk          
Intermediate 63 61 16.4 (12.9, 19.7) 8.9 (5.4, 13.7) 7.5 0.73 (0.48, 1.10) 65.1% 42.4% 22.7%
Poor 66 72 5.0 (3.6, 7.2) 3.2 (2.2, 4.7) 1.8 0.79 (0.55, 1.11) 23.9% 13.7% 10.2%
Age          
65–74 years 52 64 14.2 (10.8, 18.7) 7.3 (4.8, 11.3) 6.9 0.64 (0.42, 0.97) 59.6% 32.5% 27.2%
≥75 years 77 69 5.9 (4.5, 9.2) 3.8 (2.6, 5.1) 2.1 0.77 (0.54, 1.09) 33.8% 21.4% 12.3%
LDAC-preselected patients with AML-MRC (n = 160)
  N Median OS, months (95%CI) Difference, months Hazard ratio (95% CI) K-M Estimated 1-Year survival Difference
AZA LDAC AZA LDAC AZA LDAC
Overall 81 79 9.5 (5.9, 14.1) 4.6 (3.3, 6.4) 4.9 0.77 (0.55, 1.09) 45.3% 23.5% 21.8%
Cytogenetic risk          
Intermediate 47 33 14.1 (8.9, 17.6) 6.4 (3.8, 14.2) 7.7 0.90 (0.54, 1.50) 57.4% 34.4% 23.0%
Poor 34 46 5.6 (2.2, 9.5) 3.7 (2.2, 5.1) 1.9 0.83 (0.52, 1.33) 28.1% 15.8% 12.3%
Age          
65–74 years 26 38 14.9 (9.0, 19.6) 5.2 (3.5, 10.0) 9.7 0.68 (0.39, 1.18) 61.5% 26.3% 35.2%
≥75 years 55 41 8.8 (4.5, 12.9) 4.0 (2.8, 6.4) 4.8 0.78 (0.50, 1.22) 37.5% 20.8% 16.7%
  1. AML-MRC, AML with myelodysplasia-related changes; AZA, azacitidine; CCR, conventional care regimens; CI, confidence interval; K-M, Kaplan-Meier
  2. Hazard ratios in bold indicate statistical significance